

Quarterly Update

July 31, 2026

Australian internet of things (IoT) and healthcare technology company, Oakridge International Limited (ASX: OAK) ("Oakridge" or the "Company"), is pleased to provide the following business update alongside its Appendix 4C Quarterly Cash Flow Report for the quarter ended 30 June 2026 (the "Period").

The Company is a provider of innovative technology solutions for the healthcare sector where it develops and distributes its own range of nurse call and assistive technology hardware and software solutions for use across multiple healthcare sectors including hospitals, aged care, disability care and supported independent living.

Key Highlights

- The Company continued to make significant progress during the Period, supported by active project delivery, partner led sales activity, product development and ongoing internal systems improvement.
- Cash receipts from customers in the Period were \$770k and \$2.962million for the 12 months ended June 30, 2026 (2025:\$2.458 million).
- RTLS, enterprise reporting, annunciator firmware upgrades, mobile application development and related software and integration work all progressed during the Period.
- Strategic partner activity remained active across multiple states, supporting project opportunities, market coverage and future revenue generation.
- Internal systems alignment, quality and information security readiness work and operational planning activities continued through the Period.
- The Company raised \$349,996 from Options exercised by Montague Capital Pty Ltd, an entity associated with Mr. Con Unerkov, a Director of the Company.

Business Development and Industry Engagement

- Partner activity remained active across aged care, disability care, hospital and retirement living opportunities, including engagements involving nurse call upgrades, wireless systems, RTLS deployments and multisite programs.
- Installation activity continued across multiple care sites, with rollout progress supported by delivered stock, replacement server arrangements, customer presentations and ongoing technical support.
- Additional opportunities advanced through ongoing product demonstrations, technical submissions requests and further engagement with direct and channel prospects.
- The project pipeline continued to include both partner and direct opportunities across Australian healthcare and international markets, with several larger opportunities awaiting purchase orders, final approvals or delivery scheduling.
- Management expects current channel activity, qualified opportunities and project conversions to support revenue through FY2027.

Sales and Projects

- Project activity remained solid during the Period, with a substantial body of contracted work still to be invoiced and converted through delivery milestones.
- The active quote book remained material, comprising opportunities across a range of sectors and geographies.
- Installations and staged delivery progressed across multiple customer sites, with several jobs moving through programming, first fix, component delivery, commissioning and installation phases.
- Work with partner groups and direct customers continued across several concurrent opportunities, providing a continuing base for future revenue conversion.
- Assisted living and accommodation-related programs also continued to expand, including further integrated and assistive technology deployments in supported living environments.

Product and Technology Development

- RTLS development continued during the Period, with call point and resident pendant work completed and orders fulfilled.
- Enterprise platform development advanced further, with first stage enterprise reporting completed, demonstrations undertaken and reporting and integration features continuing toward broader deployment milestones.
- Software development progressed across single sign on related configuration and testing, mobile application development continued with core functionality operating and further reliability testing underway.
- Firmware refinement remained a focus for annunciator products, including functionality, display and volume improvements.
- Additional product planning and sourcing work continued across LCD annunciator options, nurse station monitor integration, sign in and sign out tools and a new call point specification.
- Product planning continues to track evolving nurse call standards, with the business remaining focused on compliance, product relevance and competitive positioning going forward.

Human Resources and Operations

- Project rostering and resource allocation continued to be managed around delivery requirements.
- Internal systems and process improvements remained a focus, including integration work designed to better align operational workflow, inventory visibility and reporting accuracy.
- The business also continued readiness activities for ISO 9001:2015 and ISO 27001 related certification work.

Marketing and Industry Engagement

- Brand visibility continued to build during the Period, supported by website development, digital marketing activity, partner related promotional work and conference participation.
- RTLS content and specification materials were progressed for market engagement, while website refresh and lead generation enhancement activities remained ongoing.

Related Party Payments

During the reporting period, related party payments totaling \$107,996 were made which included amounts accrued from prior periods. These payments pertain to Director and Executive Officer fees.

Other Matters

As announced on 2 January 2020, the Company completed a A\$250,000 share placement ("Placement Agreement") with Teko International Limited (Teko).

On 28 July 2020, the Company held a discussion with Teko in respect to a potential claim asserted by Teko against the Company for allegedly misrepresenting the Company's unrecorded liabilities, including the Heuresy liability payment previously disclosed, by its then directors.

The Board believes that there may be some exposure to the Company in respect to the representations made by the then Board members. If the Company were to be subject to legal action that could be taken by Teko, there could be no assurance as to the outcome or the costs required to defend any such action.

The Company will continue to discuss the issue with our legal advisors and negotiate with Teko to seek the most desirable outcome for the Company and its shareholders.

Overall Outlook

The Company will continue to assess complementary product opportunities and selected adjacent technologies that may enhance its healthcare solution offering. Areas under review include potential AI-related applications aimed at improving documentation, strengthening quality reporting, supporting compliance requirements and improving operational efficiency, although any such opportunities remain subject to ongoing evaluation, development and commercial assessment

This shareholder update has been approved by the Board of Oakridge International Limited.

Julie Edwards
Company Secretary
Oakridge International Limited

For further information, please contact: Oakridge International Limited (ASX: OAK)

P: +61 8 8223 0200.

E: info@oakridgeint.com

Forward-looking statements

This announcement contains or may contain forward-looking statements that are based on Oakridge's beliefs, assumptions and expectations and on information currently available to Oakridge. All statements that address operating performance, events or developments that Oakridge or its directors expect or anticipate will occur in the future are forward-looking statements, including, without limitation, statements as to the expectations of Oakridge or the market it operates in.

Oakridge believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Oakridge does not assume any obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.

No assurance or guarantee is, or should be taken to be, given in relation to and no reliance should be placed on, the future business performance or results of Oakridge or the likelihood that the current assumptions, estimates or outcomes will be achieved. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Oakridge International Limited

ABN

89 122 203 196

Quarter ended ("current quarter")

30 June 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	770	2,962
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(303)	(1,674)
(c) advertising and marketing	(8)	(38)
(d) leased assets	-	-
(e) staff costs	(310)	(1,181)
(f) administration and corporate costs	(111)	(490)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(1)	(5)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	349
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	37	(77)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	-

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	350	350
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	250
3.6	Repayment of borrowings	(250)	(250)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (Payments for lease liabilities)	(27)	(106)
3.10	Net cash from / (used in) financing activities	73	244

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	528	471
4.2	Net cash from / (used in) operating activities (item 1.9 above)	37	(77)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	73	244
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	638	638

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	638	528
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	638	528

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	108
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	-	-
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	37
8.2	Cash and cash equivalents at quarter end (item 4.6)	638
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	638
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1) <i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	N/A
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: N/A	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: N/A.	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

31 July 2026

Date:

The Board

Authorised by:
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg *Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.